Otsuka disclosed late-stage trial evidence for Voyxact (ocrelizumab was not; Voyxact is a monoclonal antibody) as it pursues full approval in IgA nephropathy. Separate reporting highlighted a Phase 3 result where kidney function loss slowed versus placebo after one year, but the effect came in below expectations. The data frame the remaining competitive question for IgA nephropathy therapeutics: whether Voyxact’s magnitude of benefit will translate into differentiated uptake versus existing standards and emerging competitors. Otsuka’s next steps will likely focus on how the benefit-risk profile compares in context of trial design, endpoint behavior, and patient subgroups. For providers, the disclosure adds urgency around real-world interpretability of eGFR slopes and patient-level benefit durability after initial treatment cycles.